Showing posts with label delta inflation. Show all posts
Showing posts with label delta inflation. Show all posts
Thursday, January 5, 2017

RCT Autopsy: The Differential Diagnosis of a Negative Trial

›
At many institutions, Journal Clubs meet to dissect a trial after its results are published to look for flaws, biases, shortcomings, limi...
2 comments:
Thursday, September 8, 2016

Hiding the Evidence in Plain Sight: One-sided Confidence Intervals and Noninferiority Trials

›
In the last post, I linked a video podcast of my explaining non-inferiority trials and their inherent biases.  In this videocast, I revisit...
3 comments:
Wednesday, December 23, 2015

Narrated and Abridged: There is (No) Evidence for That: Epistemic Problems in Critical Care Medicine

›
Below is the narrated video of my powerpoint presentation on Epistemic Problems in Critical Care Medicine , which provides a framework fo...
2 comments:
Wednesday, July 22, 2015

There is (No) Evidence For That: Epistemic Problems in Evidence Based Medicine

›
Below is a Power Point Presentation that I have delivered several times recently including one iteration at the SMACC conference in Chicag...
2 comments:
Friday, May 31, 2013

Over Easy? Trials of Prone Positioning in ARDS

›
Published May 20 in the  NEJM to coincide with the ATS meeting is the (latest)  Guerin et al study of Prone Positioning in ARDS .  The edi...
4 comments:
Monday, May 20, 2013

It All Hinges on the Premises: Prophylactic Platelet Transfusion in Hematologic Malignancy

›
A quick update before I proceed with the current post:   The Institute of Medicine has met and they agree with me that sodium restricti...
1 comment:
Friday, March 5, 2010

Levo your Dopa at the Door - how study design influences our interpretation of reality

›
Another excellent critical care article was published this week in NEJM, the SOAP II study: http://content.nejm.org/cgi/content/short/362/9/...
4 comments:
Monday, September 21, 2009

The unreliable assymmetric design of the RE-LY trial of Dabigatran: Heads I win, tails you lose

›
I'm growing weary of this. I hope it stops. We can adapt the diagram of non-inferiority shenanigans from the Gefitinib trial (see http:/...
8 comments:
Sunday, September 6, 2009

There's no such thing as a free lunch - unless you're running a non-inferiority trial. Gefitinib for pulmonary adenocarcinoma

›
A 20% difference in some outcome is either clinically relevant, or it is not. If A is worse than B by 19% and that's NOT clinically rele...
3 comments:
Monday, February 9, 2009

More Data on Dexmedetomidine - moving in the direction of a new standard

›
A follow-up study of dexmedetomidine (see previous blog: http://medicalevidence.blogspot.com/2007/12/dexmedetomidine-new-standard-in_16.html...
1 comment: